Trial Profile
Asunaprevir/Daclatasvir/Beclabuvir Fixed-Dose Combination Safety Surveillance in Japanese Patients With Chronic Hepatitis C (HCV) or Japanese Patients With Compensated Cirrhosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Feb 2022
Price :
$35
*
At a glance
- Drugs Asunaprevir/becabluvir/daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 07 Feb 2022 Status changed from active, no longer recruiting to completed.
- 28 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 02 Jul 2018 Planned End Date changed from 20 Nov 2019 to 14 Nov 2019.